<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893551</url>
  </required_header>
  <id_info>
    <org_study_id>BGB149-102</org_study_id>
    <secondary_id>2020-001382-36</secondary_id>
    <nct_id>NCT04893551</nct_id>
  </id_info>
  <brief_title>A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants</brief_title>
  <official_title>Phase 1b, Multicentre, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BerGenBio ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BerGenBio ASA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to assess the safety and tolerability of tilvestamab following IV&#xD;
      administration of multiple doses to participants with HGSOC who have been treated with at&#xD;
      least 1 complete course of platinum-based chemotherapy and whose disease has relapsed with&#xD;
      platinum resistance ([PRR]-HGSOC) and to determine the plasma pharmacokinetics (PK) exposure&#xD;
      by comprehensive profiling (at single dose and steady-state) of multiple ascending doses of&#xD;
      tilvestamab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>An AE is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at Screening, worsens during the study, regardless of the suspected cause of the event. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Laboratory Abnormalities</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of participants with laboratory (haematology, coagulation, clinical chemistry, serum inflammatory cytokine profile, and urinalysis) abnormalities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Vital Sign Abnormalities</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of participants with vital sign (supine blood pressure [BP], heart rate, oral temperature, and respiratory rate) abnormalities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of participants with resting triplicate 12-lead ECG abnormalities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Physical Examinations Abnormalities</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of participants with physical examinations abnormalities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Concomitant Medication Use</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of participants with concomitant medication use will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>Up to 140 days</time_frame>
    <description>Cmax will be determined directly from the concentration-time profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Up to 140 days</time_frame>
    <description>Time to Cmax will be determined directly from the concentration-time profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) From Predose (Time 0) to the end of the Dosing Period (AUC0-tau)</measure>
    <time_frame>Up to 140 days</time_frame>
    <description>AUC0-tau will be calculated using the linear-log trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Predose (Time 0) to the Time of the Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Up to 140 days</time_frame>
    <description>AUClast will be calculated using the linear-log trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Predose (Time 0) to 168 Hours Postdose (AUC0-168 )</measure>
    <time_frame>Predose up to 168 hours postdose</time_frame>
    <description>AUC0-168 is AUC from predose (time 0) to 168 hours postdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Rate Constant (Lambda[z])</measure>
    <time_frame>Up to 140 days</time_frame>
    <description>Lambda[z] will be determined by selection of at least 3 data points on the terminal phase of the concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life</measure>
    <time_frame>Up to 140 days</time_frame>
    <description>Terminal elimination half-life calculated as: ln2/Lambda[z]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL)</measure>
    <time_frame>Up to 140 days</time_frame>
    <description>CL is defined as total body clearance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-drug Antibodies (ADAs)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of participants with ADAs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Neutralizing Antibodies (NAbs)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Number of participants with NAbs will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Tilvestamab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tilvestamab at a low starting dose level (Cohort A) given via intravenous (IV) infusion every 2 weeks. Dose escalations to subsequent cohorts (Cohort B and Cohort C) will be decided by the Protocol Steering Committee (PSC) after review of all Cycle 1 (28 days cycle) safety and pharmacokinetics (PK) data up to Cycle 1 Day 22 for all participants in the ongoing cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tilvestamab</intervention_name>
    <description>Tilvestamab will be administered as IV infusion.</description>
    <arm_group_label>Tilvestamab</arm_group_label>
    <other_name>BGB149</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females of non-childbearing potential at the time of provision of informed consent&#xD;
&#xD;
          -  Ability to understand and provide written confirmation of informed consent after&#xD;
             reading study information, discussion with the investigator, and adequate time to&#xD;
             decide on participation&#xD;
&#xD;
          -  Consents to storage of study-related samples and data for exploratory use&#xD;
&#xD;
          -  Histologically confirmed HGSOC&#xD;
&#xD;
          -  Platinum-resistant relapsed disease; defined as progressive disease based on imaging&#xD;
             within &lt;= 6 months from completion of most recent regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary platinum-refractory disease (ie, progression during the first platinum regimen&#xD;
             or within 4 weeks of completion of the first platinum regimen) with rapid progression&#xD;
             and life-threatening disease manifestation&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Concurrent anticancer therapy&#xD;
&#xD;
          -  Participants who are breastfeeding&#xD;
&#xD;
          -  Known uncontrolled central nervous system metastases. Participants without known brain&#xD;
             metastases do not require radiological imaging prior to enrolment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akil Jackson</last_name>
    <role>Study Director</role>
    <affiliation>BerGenBio ASA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BerGenBio Clinical Team</last_name>
    <phone>+47 559 61 159</phone>
    <email>trialsites@bergenbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System- Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital Bergen</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College London, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Norway</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the article, after deidentification [text, tables, figures and appendices].</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication</ipd_time_frame>
    <ipd_access_criteria>Proposal should be directed to HYPERLINK &quot;mailto:clinical@bergenbio.com&quot; clinical@bergenbio.com. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

